STAA insider update: 20,967 shares from RSU vesting; 45,477 owned

Rhea-AI Filing Summary

STAAR Surgical (STAA) reported an insider equity change on Form 4. On 11/12/2025, Director Wei Jiang acquired 20,967 shares of common stock at $0 per share, following the vesting and settlement of restricted stock units (Transaction Code: M).

After this transaction, Jiang beneficially owns 45,477 shares, held directly. The RSUs were granted on May 12, 2025 and vest in three equal tranches of 20,967 shares each: on August 12, 2025, November 12, 2025, and January 12, 2026.

According to prior disclosures, Jiang is serving through fiscal 2025 as a special strategic advisor to the company’s Asia Pacific business in the temporary role of Chief of APAC Strategy; this transaction reflects vesting tied to that service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jiang Wei

(Last) (First) (Middle)

25510 COMMERCENTRE DRIVE

(Street)

LAKE FOREST CA 92630

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STAAR SURGICAL CO [ STAA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/12/2025		M		20,967(1)	A	$0	45,477	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(2)	11/12/2025		M			20,967	(1)	(1)	Common Stock	20,967	$0	20,967	D

Explanation of Responses:

1. Reflects restricted stock units (RSUs) granted to the Reporting Person on May 12, 2025. These RSUs vested as to 1/3 of the shares subject to the award (20,967 shares) on August 12, 2025 and 1/3 (20,967 shares) on November 12, 2025, and will vest as 1/3 (20,967 shares) on January 12, 2026.

2. Each RSU represents the right to receive one share of the Corporation's common stock upon vesting.

Remarks:

As disclosed in the Corporation's Current Report on Form 8-K filed on April 24, 2025, the Corporation entered into a consulting agreement with Mr. Jiang to serve as a special strategic advisor to the Corporation's Asia Pacific business through the end of fiscal 2025, in the temporary role of Chief of APAC Strategy. This Form 4 reflects the vesting of RSUs granted to Mr. Jiang in connection with such service.

	/s/ Nathaniel Sisitsky as attorney-in-fact for Wei Jiang	11/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did STAAR Surgical (STAA) disclose on this Form 4?

Director Wei Jiang acquired 20,967 shares via RSU vesting on 11/12/2025 at $0 per share (Code M).

How many STAA shares does Wei Jiang own after the transaction?

Following the transaction, Jiang beneficially owns 45,477 shares, held directly.

What is the vesting schedule for the RSUs?

The grant from May 12, 2025 vests in three tranches of 20,967 shares: Aug 12, 2025, Nov 12, 2025, and Jan 12, 2026.

What does Transaction Code M mean here?

Code M indicates the conversion of a derivative security, in this case RSUs settling into common stock.

What is Wei Jiang’s relationship to STAAR Surgical?

Jiang is a Director and is serving through fiscal 2025 as a special strategic advisor for APAC strategy.

What was the price per share for this acquisition?

The shares were acquired at $0, reflecting RSU settlement rather than an open-market purchase.